<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40878683</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1524-4628</ISSN><JournalIssue CitedMedium="Internet"><Volume>56</Volume><Issue>10</Issue><PubDate><Year>2025</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Stroke</Title><ISOAbbreviation>Stroke</ISOAbbreviation></Journal><ArticleTitle>Direct Endovascular Versus Bridging Therapy in M2 Segment Occlusion of Middle Cerebral Artery: A MR CLEAN Registry Study.</ArticleTitle><Pagination><StartPage>2866</StartPage><EndPage>2878</EndPage><MedlinePgn>2866-2878</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1161/STROKEAHA.125.051967</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The optimal strategy for managing M2 segment occlusions of the middle cerebral artery, whether with direct endovascular treatment (EVT) or bridging therapy with intravenous thrombolysis (IVT) before EVT, remains unclear. This study aimed to evaluate the effectiveness and safety of both approaches.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Patients with M2 segment occlusions of the middle cerebral artery, treated between March 2014 and December 2018, were identified from the MR CLEAN Registry (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands), a prospective, nationwide, multicenter registry of patients with acute ischemic stroke who underwent endovascular treatment during that period. They were divided into 2 groups: those who received IVT followed by EVT, and those who received EVT alone. Primary outcomes included functional outcomes at 90 days, assessed by ordinal logistic regression analysis of modified Rankin Scale (mRS) scores. Secondary outcomes included recanalization rates measured by extended Thrombolysis in Cerebral Infarction scores, dichotomized mRS scores (0-1, 0-2, and 0-3), death at 90 days, and symptomatic intracranial hemorrhage. All analyses were performed using both unadjusted and adjusted multivariable approaches, with adjustment achieved through inverse probability of treatment weighting to account for baseline imbalances, including age, baseline National Institutes of Health Stroke Scale score, prior stroke, history of atrial fibrillation, anticoagulant use, and transfer status.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 539 patients with M2 occlusions were included in the analysis: 377 received IVT+EVT and 162 received EVT alone. The median age was significantly lower in the IVT+EVT group compared with the EVT-alone group (71 [61-79] versus 74 [65-81]; <i>P</i>=0.01), whereas the proportion of male patients was similar between groups (55.2% versus 51.9%; <i>P</i>=0.15). At 90 days, inverse probability of treatment weighting analysis showed that IVT+EVT was significantly associated with reduced disability compared with EVT alone (adjusted common odds ratio for mRS score, 1.52 [95% CI, 1.04-2.21]; <i>P</i>=0.03). Dichotomized functional outcomes and mortality were numerically in favor of IVT+EVT, with higher rates of mRS score of 0 to 1 (38.9% versus 29.7%, aOR, 1.40 [95% CI, 0.85-2.30]; <i>P</i>=0.19), mRS score of 0 to 2 (57.8% versus 46.5%; aOR, 1.42 [95% CI, 0.88-2.29]; <i>P</i>=0.15), and mRS score of 0 to 3 (73.2% versus 59.4%, aOR, 1.54 [95% CI, 0.94-2.51]; <i>P</i>=0.09), as well as lower 90-day mortality (17.2% versus 25.8%; aOR, 0.83 [95% CI, 0.47-1.45]; <i>P</i>=0.51). In contrast, recanalization rates and symptomatic intracranial hemorrhage were numerically in favor of EVT alone, but all these differences were not statistically significant (<i>P</i>&gt;0.05).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Bridging therapy may yield superior functional outcomes compared with EVT alone for patients with the middle cerebral artery-M2 occlusions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Doheim</LastName><ForeName>Mohamed F</ForeName><Initials>MF</Initials><Identifier Source="ORCID">0000-0001-8279-5078</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Stroke Institute, University of Pittsburgh Medical Center, PA (M.F.D., R.G.N.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology (R.R.M.M.K., J.S., R.J.v.O., M.F.D.), Maastricht University Medical Center+, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knapen</LastName><ForeName>Robrecht R M M</ForeName><Initials>RRMM</Initials><Identifier Source="ORCID">0000-0003-4677-3685</Identifier><AffiliationInfo><Affiliation>Departments of Radiology and Nuclear Medicine (R.R.M.M.K., C.v.d.L., W.H.v.Z.), Maastricht University Medical Center+, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology (R.R.M.M.K., J.S., R.J.v.O., M.F.D.), Maastricht University Medical Center+, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School for Cardiovascular Diseases Maastricht (CARIM), Maastricht University, the Netherlands (R.R.M.M.K., R.J.v.O., W.H.v.Z.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, the Netherlands (R.R.M.M.K., C.v.d.L., W.H.v.Z.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staals</LastName><ForeName>Julie</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9502-6937</Identifier><AffiliationInfo><Affiliation>Department of Neurology (R.R.M.M.K., J.S., R.J.v.O., M.F.D.), Maastricht University Medical Center+, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schonewille</LastName><ForeName>Wouter J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, St. Antonius Hospital, Nieuwegein, the Netherlands (W.J.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dippel</LastName><ForeName>Diederik W J</ForeName><Initials>DWJ</Initials><Identifier Source="ORCID">0000-0002-9234-3515</Identifier><AffiliationInfo><Affiliation>Departments of Neurology (D.W.J.D.), Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Es</LastName><ForeName>Adriaan C G M</ForeName><Initials>ACGM</Initials><Identifier Source="ORCID">0000-0002-4820-5051</Identifier><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, Leiden University Medical Center, the Netherlands (A.C.G.M.v.E.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lingsma</LastName><ForeName>Hester F</ForeName><Initials>HF</Initials><Identifier Source="ORCID">0000-0003-2063-9533</Identifier><AffiliationInfo><Affiliation>Departments of Public Health (H.F.L.), Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Leij</LastName><ForeName>Christiaan</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-0170-1012</Identifier><AffiliationInfo><Affiliation>Departments of Radiology and Nuclear Medicine (R.R.M.M.K., C.v.d.L., W.H.v.Z.), Maastricht University Medical Center+, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Institute for Oncology and Reproduction (GROW), School for Oncology and Reproduction (C.v.d.L.), Maastricht University, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, the Netherlands (R.R.M.M.K., C.v.d.L., W.H.v.Z.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Majoie</LastName><ForeName>Charles B</ForeName><Initials>CB</Initials><Identifier Source="ORCID">0000-0002-7600-9568</Identifier><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, University of Amsterdam, the Netherlands (C.B.M.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nogueira</LastName><ForeName>Raul G</ForeName><Initials>RG</Initials><Identifier Source="ORCID">0000-0003-4532-153X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Stroke Institute, University of Pittsburgh Medical Center, PA (M.F.D., R.G.N.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Oostenbrugge</LastName><ForeName>Robert J</ForeName><Initials>RJ</Initials><Identifier Source="ORCID">0000-0003-1032-9099</Identifier><AffiliationInfo><Affiliation>Department of Neurology (R.R.M.M.K., J.S., R.J.v.O., M.F.D.), Maastricht University Medical Center+, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School for Cardiovascular Diseases Maastricht (CARIM), Maastricht University, the Netherlands (R.R.M.M.K., R.J.v.O., W.H.v.Z.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Maastricht University Medical Center, the Netherlands (R.J.v.O.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Zwam</LastName><ForeName>Wim H</ForeName><Initials>WH</Initials><Identifier Source="ORCID">0000-0003-1631-7056</Identifier><AffiliationInfo><Affiliation>Departments of Radiology and Nuclear Medicine (R.R.M.M.K., C.v.d.L., W.H.v.Z.), Maastricht University Medical Center+, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School for Cardiovascular Diseases Maastricht (CARIM), Maastricht University, the Netherlands (R.R.M.M.K., R.J.v.O., W.H.v.Z.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, the Netherlands (R.R.M.M.K., C.v.d.L., W.H.v.Z.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>MR CLEAN Registry Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Stroke</MedlineTA><NlmUniqueID>0235266</NlmUniqueID><ISSNLinking>0039-2499</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005343">Fibrinolytic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057510" MajorTopicYN="Y">Endovascular Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020244" MajorTopicYN="Y">Infarction, Middle Cerebral Artery</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015912" MajorTopicYN="Y">Thrombolytic Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000083242" MajorTopicYN="Y">Ischemic Stroke</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005343" MajorTopicYN="N">Fibrinolytic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">intracranial hemorrhage</Keyword><Keyword MajorTopicYN="N">ischemic stroke</Keyword><Keyword MajorTopicYN="N">middle cerebral artery</Keyword><Keyword MajorTopicYN="N">mortality</Keyword></KeywordList><CoiStatement>Dr Staals reports compensation from Medtronic for other services. Dr Majoie reports stock holdings in Nico-lab; grants from Health Evaluation the Netherlands to other; grants from Toegepast Wetenschappelijk Instituut voor Neuromodulatie (TWIN) Foundation to other; grants from Boehringer Ingelheim to other; grants from Dutch Heart Foundation to other; grants from Stryker Corporation to other; and grants from European Commission to other. Dr Nogueira reports stock options in Reist/Q&#x2019;Apel Medical; compensation from Shanghai Wallaby for consultant services; stock holdings in Quantanosis AI; compensation from Corindus Inc for consultant services; stock holdings in Piraeus Medical; compensation from Perfuze for consultant services; compensation from Vesalio for consultant services; compensation from Philips for consultant services; compensation from Brainomix for consultant services; compensation from RapidPulse for consultant services; stock options in viz-AI; compensation from Biogen Inc for consultant services; stock options in Viseon Inc; compensation from Anaconda Biomed for consultant services; compensation from phenox Inc for consultant services; grants from Cerenovus; compensation from NeuroVasc Technologies Inc for consultant services; compensation from Synchron for data and safety monitoring services; stock options in Corindus Inc; compensation from Hybernia for consultant services; compensation from Ceretrieve for consultant services; compensation from Cerenovus for consultant services; compensation from Imperative Care for consultant services; compensation from Genentech for consultant services; compensation from Medtronic USA Inc for consultant services; compensation from Imperative Care Inc for consultant services; stock options in Truvic; stock options in RapidPulse; stock holdings in Brain4Care; grants from Stryker; compensation from Prolong Pharmaceuticals for consultant services; stock options in Brainomix; stock options in Perfuze; stock options in Ceretrieve; compensation from Cerebrotech for consultant services; stock options in Cerebrotech; compensation from Boehringer Ingelheim for consultant services; compensation from viz-AI for consultant services; stock options in Vesalio; compensation from Corindus Vascular Robotics for consultant services; compensation from Stryker Corporation for consultant services; and compensation from Astrocyte for consultant services. Dr van Zwam reports grants from Johnson and Johnson International; grants from Bayer HealthCare Pharmaceuticals Inc; grants from Stryker Corporation; compensation from Philips for data and safety monitoring services; and employment by Maastricht Universitair Medisch Centrum. The other authors report no conflicts.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>van der Lugt</LastName><ForeName>Aad</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roos</LastName><ForeName>Yvo B W E M</ForeName><Initials>YBWEM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boiten</LastName><ForeName>Jelis</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albert Vos</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jansen</LastName><ForeName>Ivo G H</ForeName><Initials>IGH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mulder</LastName><ForeName>Maxim J H L</ForeName><Initials>MJHL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldhoorn</LastName><ForeName>Robert-Jan B</ForeName><Initials>RB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Compagne</LastName><ForeName>Kars C J</ForeName><Initials>KCJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kappelhof</LastName><ForeName>Manon</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brouwer</LastName><ForeName>Josje</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hinsenveld</LastName><ForeName>Wouter H</ForeName><Initials>WH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roozenbeek</LastName><ForeName>Bob</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>van der Lugt</LastName><ForeName>Aad</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roos</LastName><ForeName>Yvo B W E M</ForeName><Initials>YBWEM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Emmer</LastName><ForeName>Bart J</ForeName><Initials>BJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coutinho</LastName><ForeName>Jonathan M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albert Vos</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wermer</LastName><ForeName>Marieke J H</ForeName><Initials>MJH</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Walderveen</LastName><ForeName>Marianne A A</ForeName><Initials>MAA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hofmeijer</LastName><ForeName>Jeannette</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martens</LastName><ForeName>Jasper M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lycklama &#xc0; Nijeholt</LastName><ForeName>Geert J</ForeName><Initials>GJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boiten</LastName><ForeName>Jelis</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Bruijn</LastName><ForeName>Sebastiaan F</ForeName><Initials>SF</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Dijk</LastName><ForeName>Lukas C</ForeName><Initials>LC</Initials></Investigator><Investigator ValidYN="Y"><LastName>van der Worp</LastName><ForeName>H Bart</ForeName><Initials>HB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lo</LastName><ForeName>Rob H</ForeName><Initials>RH</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Dijk</LastName><ForeName>Ewoud J</ForeName><Initials>EJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boogaarts</LastName><ForeName>Hieronymus D</ForeName><Initials>HD</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Vries</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Kort</LastName><ForeName>Paul L M</ForeName><Initials>PLM</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Tuijl</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peluso</LastName><ForeName>Jo P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fransen</LastName><ForeName>Puck</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>van den Berg</LastName><ForeName>Jan S P</ForeName><Initials>JSP</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Hasselt</LastName><ForeName>Boudewijn A A M</ForeName><Initials>BAAM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aerden</LastName><ForeName>Leo A M</ForeName><Initials>LAM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dallinga</LastName><ForeName>Ren&#xe9; J</ForeName><Initials>RJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uyttenboogaart</LastName><ForeName>Maarten</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eschgi</LastName><ForeName>Omid</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bokkers</LastName><ForeName>Reinoud P H</ForeName><Initials>RPH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schreuder</LastName><ForeName>Tobien H C M L</ForeName><Initials>THCML</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heijboer</LastName><ForeName>Roel J J</ForeName><Initials>RJJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keizer</LastName><ForeName>Koos</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yo</LastName><ForeName>Lonneke S F</ForeName><Initials>LSF</Initials></Investigator><Investigator ValidYN="Y"><LastName>den Hertog</LastName><ForeName>Heleen M</ForeName><Initials>HM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sturm</LastName><ForeName>Emiel J C</ForeName><Initials>EJC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brouwers</LastName><ForeName>Paul J A M</ForeName><Initials>PJAM</Initials></Investigator><Investigator ValidYN="Y"><LastName>van der Lugt</LastName><ForeName>Aad</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lycklama &#xc0; Nijeholt</LastName><ForeName>Geert J</ForeName><Initials>GJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Walderveen</LastName><ForeName>Marianne A A</ForeName><Initials>MAA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sprengers</LastName><ForeName>Marieke E S</ForeName><Initials>MES</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jenniskens</LastName><ForeName>Sjoerd F M</ForeName><Initials>SFM</Initials></Investigator><Investigator ValidYN="Y"><LastName>van den Berg</LastName><ForeName>Ren&#xe9;</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yoo</LastName><ForeName>Albert J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beenen</LastName><ForeName>Ludo F M</ForeName><Initials>LFM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Postma</LastName><ForeName>Alida A</ForeName><Initials>AA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roosendaal</LastName><ForeName>Stefan D</ForeName><Initials>SD</Initials></Investigator><Investigator ValidYN="Y"><LastName>van der Kallen</LastName><ForeName>Bas F W</ForeName><Initials>BFW</Initials></Investigator><Investigator ValidYN="Y"><LastName>van den Wijngaard</LastName><ForeName>Ido R</ForeName><Initials>IR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Emmer</LastName><ForeName>Bart J</ForeName><Initials>BJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martens</LastName><ForeName>Jasper M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yo</LastName><ForeName>Lonneke S F</ForeName><Initials>LSF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albert Vos</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bot</LastName><ForeName>Joost</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Doormaal</LastName><ForeName>Pieter-Jan</ForeName><Initials>PJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meijer</LastName><ForeName>Anton</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghariq</LastName><ForeName>Elyas</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bokkers</LastName><ForeName>Reinoud P H</ForeName><Initials>RPH</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Proosdij</LastName><ForeName>Marc P</ForeName><Initials>MP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Menno Krietemeijer</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peluso</LastName><ForeName>Jo P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boogaarts</LastName><ForeName>Hieronymus D</ForeName><Initials>HD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lo</LastName><ForeName>Rob</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dinkelaar</LastName><ForeName>Wouter</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Appelman</LastName><ForeName>Auke P A</ForeName><Initials>APA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hammer</LastName><ForeName>Bas</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pegge</LastName><ForeName>Sjoert</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>van der Hoorn</LastName><ForeName>Anouk</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vinke</LastName><ForeName>Saman</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cornelissen</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brans</LastName><ForeName>Rutger</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>van der Lugt</LastName><ForeName>Aad</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roos</LastName><ForeName>Yvo B W E M</ForeName><Initials>YBWEM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lycklama &#xc0; Nijeholt</LastName><ForeName>Geert J</ForeName><Initials>GJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boiten</LastName><ForeName>Jelis</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albert Vos</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hofmeijer</LastName><ForeName>Jeannette</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martens</LastName><ForeName>Jasper M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bart van der Worp</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lo</LastName><ForeName>Rob H</ForeName><Initials>RH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hofmeijer</LastName><ForeName>Jeannette</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flach</LastName><ForeName>H Zwenneke</ForeName><Initials>HZ</Initials></Investigator><Investigator ValidYN="Y"><LastName>El Ghannouti</LastName><ForeName>Naziha</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sterrenberg</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pellikaan</LastName><ForeName>Wilma</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sprengers</LastName><ForeName>Rita</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elfrink</LastName><ForeName>Marjan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simons</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vossers</LastName><ForeName>Marjolein</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Meris</LastName><ForeName>Joke</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vermeulen</LastName><ForeName>Tamara</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geerlings</LastName><ForeName>Annet</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Vemde</LastName><ForeName>Gina</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simons</LastName><ForeName>Tiny</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Messchendorp</LastName><ForeName>Gert</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nicolaij</LastName><ForeName>Nynke</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bongenaar</LastName><ForeName>Hester</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bodde</LastName><ForeName>Karin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sandra Kleijn</LastName><ForeName>Delft</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lodico</LastName><ForeName>Jasmijn</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Droste</LastName><ForeName>Hanneke</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wollaert</LastName><ForeName>Maureen</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Verheesen</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jeurrissen</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bos</LastName><ForeName>Erna</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Drabbe</LastName><ForeName>Yvonne</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sandiman</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aaldering</LastName><ForeName>Nicoline</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zweedijk</LastName><ForeName>Berber</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vervoort</LastName><ForeName>Jocova</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ponjee</LastName><ForeName>Eva</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Romviel</LastName><ForeName>Sharon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kanselaar</LastName><ForeName>Karin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barning</LastName><ForeName>Denn</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Venema</LastName><ForeName>Esmee</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chalos</LastName><ForeName>Vicky</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geuskens</LastName><ForeName>Ralph R</ForeName><Initials>RR</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Straaten</LastName><ForeName>Tim</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ergezen</LastName><ForeName>Saliha</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harmsma</LastName><ForeName>Roger R M</ForeName><Initials>RRM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Muijres</LastName><ForeName>Daan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Jong</LastName><ForeName>Anouk</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berkhemer</LastName><ForeName>Olvert A</ForeName><Initials>OA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boers</LastName><ForeName>Anna M M</ForeName><Initials>AMM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huguet</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Groot</LastName><ForeName>P F C</ForeName><Initials>PFC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mens</LastName><ForeName>Marieke A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Kranendonk</LastName><ForeName>Katinka R</ForeName><Initials>KR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Treurniet</LastName><ForeName>Kilian M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tolhuisen</LastName><ForeName>Manon L</ForeName><Initials>ML</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alves</LastName><ForeName>Heitor</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weterings</LastName><ForeName>Annick J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kirkels</LastName><ForeName>Eleonora L F</ForeName><Initials>ELF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Voogd</LastName><ForeName>Eva J H F</ForeName><Initials>EJHF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schupp</LastName><ForeName>Lieve M</ForeName><Initials>LM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Collette</LastName><ForeName>Sabine L</ForeName><Initials>SL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Groot</LastName><ForeName>Adrien E D</ForeName><Initials>AED</Initials></Investigator><Investigator ValidYN="Y"><LastName>LeCouffe</LastName><ForeName>Natalie E</ForeName><Initials>NE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Konduri</LastName><ForeName>Praneeta R</ForeName><Initials>PR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prasetya</LastName><ForeName>Haryadi</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arrarte-Terreros</LastName><ForeName>Nerea</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramos</LastName><ForeName>Lucas A</ForeName><Initials>LA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boodt</LastName><ForeName>Nikki</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pirson</LastName><ForeName>F Anne V</ForeName><Initials>FAV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bruggeman</LastName><ForeName>Agnetha A E</ForeName><Initials>AAE</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>22</Day><Hour>18</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>29</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>29</Day><Hour>5</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40878683</ArticleId><ArticleId IdType="pmc">PMC12447822</ArticleId><ArticleId IdType="doi">10.1161/STROKEAHA.125.051967</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goyal M, Menon BK, Van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, D&#xe1;valos A, Majoie CB, van Der Lugt A, De Miquel MA, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387:1723&#x2013;1731. doi: 10.1016/S0140-6736(16)00163-X</Citation><ArticleIdList><ArticleId IdType="pubmed">26898852</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovin TG, Nogueira RG, Lansberg MG, Demchuk AM, Martins SO, Mocco J, Ribo M, Jadhav AP, Ortega-Gutierrez S, Hill MD, et al. Thrombectomy for anterior circulation stroke beyond 6 h from time last known well (AURORA): a systematic review and individual patient data meta-analysis. Lancet. 2022;399:249&#x2013;258. doi: 10.1016/s0140-6736(21)01341-6</Citation><ArticleIdList><ArticleId IdType="pubmed">34774198</ArticleId></ArticleIdList></Reference><Reference><Citation>Doheim MF, Hagrass AI, Elrefaey M, Al-Bayati AR, Bhatt NR, Lang M, Starr M, Rocha M, Gross B, Nogueira RG. From therapeutic nihilism to armamentarium: a meta-analysis of randomized clinical trials assessing safety and efficacy of endovascular therapy for acute large ischemic strokes [published online April 23, 2023]. Interv Neuroradiol. doi: 10.1177/15910199231170681</Citation><ArticleIdList><ArticleId IdType="pubmed">37082795</ArticleId></ArticleIdList></Reference><Reference><Citation>Lima FO, Furie KL, Silva GS, Lev MH, Camargo EC, Singhal AB, Harris GJ, Halpern EF, Koroshetz WJ, Smith WS, et al. Prognosis of untreated strokes due to anterior circulation proximal intracranial arterial occlusions detected by use of computed tomography angiography. JAMA Neurol. 2014;71:151&#x2013;157. doi: 10.1001/jamaneurol.2013.5007</Citation><ArticleIdList><ArticleId IdType="pubmed">24323077</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith WS, Lev MH, English JD, Camargo EC, Chou M, Johnston SC, Gonzalez G, Schaefer PW, Dillon WP, Koroshetz WJ, et al. Significance of large vessel intracranial occlusion causing acute ischemic stroke and TIA. Stroke. 2009;40:3834&#x2013;3840. doi: 10.1161/strokeaha.109.561787</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796543</ArticleId><ArticleId IdType="pubmed">19834014</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal M, Ospel JM, Ganesh A, Dowlatshahi D, Volders D, M&#xf6;hlenbruch MA, Jumaa MA, Nimjee SM, Booth TC, Buck BH, et al. Endovascular treatment of stroke due to medium-vessel occlusion. N Engl J Med. 2025;392:1385&#x2013;1395. doi: 10.1056/nejmoa2411668</Citation><ArticleIdList><ArticleId IdType="pubmed">39908448</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychogios M, Brehm A, Ribo M, Rizzo F, Strbian D, R&#xe4;ty S, Arenillas JF, Mart&#xed;nez-Gald&#xe1;mez M, Hajdu SD, Michel P, et al. Endovascular treatment for stroke due to occlusion of medium or distal vessels. N Engl J Med. 2025;392:1374&#x2013;1384. doi: 10.1056/nejmoa2408954</Citation><ArticleIdList><ArticleId IdType="pubmed">39908430</ArticleId></ArticleIdList></Reference><Reference><Citation>Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019;50:e344&#x2013;e418. doi: 10.1161/STR.0000000000000211</Citation><ArticleIdList><ArticleId IdType="pubmed">31662037</ArticleId></ArticleIdList></Reference><Reference><Citation>Turc G, Tsivgoulis G, Audebert HJ, Boogaarts H, Bhogal P, De Marchis GM, Fonseca AC, Khatri P, Mazighi M, de La Ossa NP, et al. European Stroke Organisation (ESO)&#x2013;European Society for Minimally Invasive Neurological Therapy (ESMINT) expedited recommendation on indication for intravenous thrombolysis before mechanical thrombectomy in patients with acute ischemic stroke and anterior circulation large vessel occlusion. J Neurointerv Surg. 2022;14:209&#x2013;227. doi: 10.1136/neurintsurg-2021-018589</Citation><ArticleIdList><ArticleId IdType="pubmed">35115395</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon BK, Hill MD, Davalos A, Roos YB, Campbell BC, Dippel DW, Guillemin F, Saver JL, van der Lugt A, Demchuk AM, et al. Efficacy of endovascular thrombectomy in patients with M2 segment middle cerebral artery occlusions: meta-analysis of data from the HERMES collaboration. J Neurointerv Surg. 2019;11:1065&#x2013;1069. doi: 10.1136/neurintsurg-2018-014678</Citation><ArticleIdList><ArticleId IdType="pubmed">30975736</ArticleId></ArticleIdList></Reference><Reference><Citation>Jumaa MA, Castonguay AC, Salahuddin H, Jadhav AP, Limaye K, Farooqui M, Zaidi SF, Mueller-Kronast N, Liebeskind DS, Zaidat OO, et al. Middle cerebral artery M2 thrombectomy in the STRATIS registry. Stroke. 2021;52:3490&#x2013;3496. doi: 10.1161/strokeaha.120.033951</Citation><ArticleIdList><ArticleId IdType="pubmed">34311566</ArticleId></ArticleIdList></Reference><Reference><Citation>Limaye K, Koo AB, Havenon A, Kasab SA, Bohnstedt B, Maier IL, Psychogios MN, Wolfe S, Arthur A, Kan P, et al. ; Stroke Thrombectomy and Aneurysm Registry (STAR) Collaborators. Safety and efficacy of MCA&#x2010;M2 thrombectomy in delayed time window: a propensity score analysis from the STAR registry. Stroke Vasc Interv Neurol. 2023;3:e000664. doi: 10.1161/svin.122.000664</Citation></Reference><Reference><Citation>Majoie CB, Cavalcante F, Gralla J, Yang P, Kaesmacher J, Treurniet KM, Kappelhof M, Yan B, Suzuki K, Zhang Y, et al. Value of intravenous thrombolysis in endovascular treatment for large-vessel anterior circulation stroke: individual participant data meta-analysis of six randomised trials. Lancet. 2023;402:965&#x2013;974. doi: 10.1016/S0140-6736(23)01142-X</Citation><ArticleIdList><ArticleId IdType="pubmed">37640037</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang P, Zhang Y, Zhang L, Zhang Y, Treurniet KM, Chen W, Peng Y, Han H, Wang J, Wang S, et al. Endovascular thrombectomy with or without intravenous alteplase in acute stroke. N Engl J Med. 2020;382:1981&#x2013;1993. doi: 10.1056/NEJMoa2001123</Citation><ArticleIdList><ArticleId IdType="pubmed">32374959</ArticleId></ArticleIdList></Reference><Reference><Citation>Zi W, Qiu Z, Li F, Sang H, Wu D, Luo W, Liu S, Yuan J, Song J, Shi Z, et al. ; DEVT Trial Investigators. Effect of endovascular treatment alone vs intravenous alteplase plus endovascular treatment on functional independence in patients with acute ischemic stroke: the DEVT randomized clinical trial. JAMA. 2021;325:234&#x2013;243. doi: 10.1001/jama.2020.23523</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7816099</ArticleId><ArticleId IdType="pubmed">33464335</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki K, Matsumaru Y, Takeuchi M, Morimoto M, Kanazawa R, Takayama Y, Kamiya Y, Shigeta K, Okubo S, Hayakawa M, et al. Effect of mechanical thrombectomy without vs with intravenous thrombolysis on functional outcome among patients with acute ischemic stroke: the SKIP randomized clinical trial. JAMA. 2021;325:244&#x2013;253. doi: 10.1001/jama.2020.23522</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7816103</ArticleId><ArticleId IdType="pubmed">33464334</ArticleId></ArticleIdList></Reference><Reference><Citation>LeCouffe NE, Kappelhof M, Treurniet KM, Rinkel LA, Bruggeman AE, Berkhemer OA, Wolff L, van Voorst H, Tolhuisen ML, Dippel DW, et al. A randomized trial of intravenous alteplase before endovascular treatment for stroke. N Engl J Med. 2021;385:1833&#x2013;1844. doi: 10.1056/nejmoa2107727</Citation><ArticleIdList><ArticleId IdType="pubmed">34758251</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer U, Kaesmacher J, Strbian D, Eker O, Cognard C, Plattner PS, B&#xfc;tikofer L, Mordasini P, Deppeler S, Pereira VM, et al. Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke: an open-label, blinded-outcome, randomised non-inferiority trial. Lancet. 2022;400:104&#x2013;115. doi: 10.1016/S0140-6736(22)00537-2</Citation><ArticleIdList><ArticleId IdType="pubmed">35810756</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell PJ, Yan B, Churilov L, Dowling RJ, Bush SJ, Bivard A, Huo XC, Wang G, Zhang SY, Ton MD, et al. Endovascular thrombectomy versus standard bridging thrombolytic with endovascular thrombectomy within 4&#xb7;5 h of stroke onset: an open-label, blinded-endpoint, randomised non-inferiority trial. Lancet. 2022;400:116&#x2013;125. doi: 10.1016/s0140-6736(22)00564-5</Citation><ArticleIdList><ArticleId IdType="pubmed">35810757</ArticleId></ArticleIdList></Reference><Reference><Citation>Nogueira RG, Doheim MF, Al-Bayati AR, Lee JS, Haussen DC, Mohammaden M, Lang M, Starr M, Rocha M, da C&#xe2;mara CP, et al. Distal medium vessel occlusion strokes: understanding the present and paving the way for a better future. J Stroke. 2024;26:190&#x2013;202. doi: 10.5853/jos.2023.02649</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11164590</ArticleId><ArticleId IdType="pubmed">38836268</ArticleId></ArticleIdList></Reference><Reference><Citation>Terreros NA, Bruggeman AA, Swijnenburg IS, van Meenen LC, Groot AE, Coutinho JM, Roos YB, Emmer BJ, Beenen LF, van Bavel E, et al. Early recanalization in large-vessel occlusion stroke patients transferred for endovascular treatment. J Neurointerv Surg. 2022;14:480&#x2013;484. doi: 10.1136/neurintsurg-2021-017441</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9016237</ArticleId><ArticleId IdType="pubmed">33986112</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen IG, Mulder MJ, Goldhoorn RJB; MR CLEAN Registry Investigators. Endovascular treatment for acute ischaemic stroke in routine clinical practice: prospective, observational cohort study (MR CLEAN Registry). BMJ. 2018;360:k949. doi: 10.1136/bmj.k949</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5844245</ArticleId><ArticleId IdType="pubmed">29523557</ArticleId></ArticleIdList></Reference><Reference><Citation>Compagne KC, Kappelhof M, Hinsenveld WH, Brouwer J, Goldhoorn RJB, Uyttenboogaart M, Bokkers RP, Schonewille WJ, Martens JM, Hofmeijer J, et al. Improvements in endovascular treatment for acute ischemic stroke: a longitudinal study in the MR CLEAN Registry. Stroke. 2022;53:1863&#x2013;1872. doi: 10.1161/STROKEAHA.121.034919</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9126265</ArticleId><ArticleId IdType="pubmed">35135323</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinsenveld WH, Brouwer J, den Hartog SJ, Bruggeman A, Kappelhof M, Jansen IG, Mulder MJ, Compagne KC, Goldhoorn RJB, Lingsma H, et al. National trends in patient characteristics, interventional techniques and outcomes of endovascular treatment for acute ischaemic stroke: final results of the MR CLEAN Registry (2014&#x2013;2018) [published online May 2, 2025]. Eur Stroke J. doi: 10.1177/23969873251334271</Citation><ArticleIdList><ArticleId IdType="pmc">PMC12049364</ArticleId><ArticleId IdType="pubmed">40317163</ArticleId></ArticleIdList></Reference><Reference><Citation>Compagne KC, van der Sluijs PM, Van Den Wijngaard IR, Roozenbeek B, Mulder MJ, van Zwam WH, Emmer BJ, Majoie CB, Yoo AJ, Lycklama &#xe0; Nijeholt GJ, et al. Endovascular treatment: the role of dominant caliber M2 segment occlusion in ischemic stroke. Stroke. 2019;50:419&#x2013;427. doi: 10.1161/STROKEAHA.118.023117</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6358188</ArticleId><ArticleId IdType="pubmed">31287757</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan I, Demchuk A, Hopyan J, Zhang L, Gladstone D, Wong K, Martin M, Symons S, Fox A, Aviv R. CT angiography clot burden score and collateral score: correlation with clinical and radiologic outcomes in acute middle cerebral artery infarct. AJNR Am J Neuroradiol. 2009;30:525&#x2013;531. doi: 10.3174/ajnr.a1408</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7051470</ArticleId><ArticleId IdType="pubmed">19147716</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber PA, Demchuk AM, Zhang J, Buchan AM. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. Lancet. 2000;355:1670&#x2013;1674. doi: 10.1016/s0140-6736(00)02237-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10905241</ArticleId></ArticleIdList></Reference><Reference><Citation>Liebeskind DS, Bracard S, Guillemin F, Jahan R, Jovin TG, Majoie CB, Mitchell PJ, van Der Lugt A, Menon BK, San Rom&#xe1;n L, et al. eTICI reperfusion: defining success in endovascular stroke therapy. J Neurointerv Surg. 2019;11:433&#x2013;438. doi: 10.1136/neurintsurg-2018-014127</Citation><ArticleIdList><ArticleId IdType="pubmed">30194109</ArticleId></ArticleIdList></Reference><Reference><Citation>von Kummer R, Broderick JP, Campbell BC, Demchuk A, Goyal M, Hill MD, Treurniet KM, Majoie CB, Marquering HA, Mazya MV, et al. The Heidelberg bleeding classification: classification of bleeding events after ischemic stroke and reperfusion therapy. Stroke. 2015;46:2981&#x2013;2986. doi: 10.1161/strokeaha.115.010049</Citation><ArticleIdList><ArticleId IdType="pubmed">26330447</ArticleId></ArticleIdList></Reference><Reference><Citation>Almekhlafi M, Davalos A, Bonafe A, Chapot R, Gralla J, Pereira V, Goyal M. Impact of age and baseline NIHSS scores on clinical outcomes in the mechanical thrombectomy using Solitaire FR in acute ischemic stroke study. AJNR Am J Neuroradiol. 2014;35:1337&#x2013;1340. doi: 10.3174/ajnr.a3855</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7966577</ArticleId><ArticleId IdType="pubmed">24557701</ArticleId></ArticleIdList></Reference><Reference><Citation>Rost NS, Bottle A, Lee JM, Randall M, Middleton S, Shaw L, Thijs V, Rinkel GJ, Hemmen TM; Global Comparators Stroke GOAL Collaborators. Stroke severity is a crucial predictor of outcome: an international prospective validation study. J Am Heart Assoc. 2016;5:e002433. doi: 10.1161/JAHA.115.002433</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4859362</ArticleId><ArticleId IdType="pubmed">26796252</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, Wood AM, Carpenter JR. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 2009;338:b2393. doi: 10.1136/bmj.b2393</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2714692</ArticleId><ArticleId IdType="pubmed">19564179</ArticleId></ArticleIdList></Reference><Reference><Citation>White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011;30:377&#x2013;399. doi: 10.1002/sim.4067</Citation><ArticleIdList><ArticleId IdType="pubmed">21225900</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamba M, Gilberti N, Premi E, Costa A, Frigerio M, Mardighian D, Vergani V, Spezi R, Delrio I, Morotti A, et al. Intravenous fibrinolysis plus endovascular thrombectomy versus direct endovascular thrombectomy for anterior circulation acute ischemic stroke: clinical and infarct volume results. BMC Neurol. 2019;19:1&#x2013;6. doi: 10.1186/s12883-019-1341-3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6540520</ArticleId><ArticleId IdType="pubmed">31142273</ArticleId></ArticleIdList></Reference><Reference><Citation>Balodis A, Radzina M, Miglane E, Rudd A, Millers A, Savlovskis J, Kupcs K. Endovascular thrombectomy in anterior circulation stroke and clinical value of bridging with intravenous thrombolysis. Acta Radiol. 2019;60:308&#x2013;314. doi: 10.1177/0284185118780897</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6378397</ArticleId><ArticleId IdType="pubmed">29874923</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou H, Zhong W, Zhang T, Xu C, Zhong G, Xie G, Zhang B, Chen H, Wang E, Xu D, et al. ; CASE-II Study Group. Comparing outcomes of thrombectomy versus intravenous thrombolysis based on middle cerebral artery M2 occlusion features. Stroke. 2024;55:1592&#x2013;1600. doi: 10.1161/strokeaha.123.044986</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11122739</ArticleId><ArticleId IdType="pubmed">38787930</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidale S, Romoli M, Agostoni EC. Endovascular treatment versus intravenous thrombolysis alone in isolated M2 occlusion: a meta-analysis. Neurol Sci. 2021;42:4221&#x2013;4224. doi: 10.1007/s10072-021-05124-2</Citation><ArticleIdList><ArticleId IdType="pubmed">33586082</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon BK, Al-Ajlan FS, Najm M, Puig J, Castellanos M, Dowlatshahi D, Calleja A, Sohn SI, Ahn SH, Poppe A, et al. ; INTERRSeCT Study Investigators. Association of clinical, imaging, and thrombus characteristics with recanalization of visible intracranial occlusion in patients with acute ischemic stroke. JAMA. 2018;320:1017&#x2013;1026. doi: 10.1001/jama.2018.12498</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6143104</ArticleId><ArticleId IdType="pubmed">30208455</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrarte Terreros N, Stolp J, Bruggeman AA, Swijnenburg IS, Lopes RR, van Meenen LC, Groot AE, Kappelhof M, Coutinho JM, Roos YB, et al. ; MR CLEAN Registry investigators. Thrombus imaging characteristics to predict early recanalization in anterior circulation large vessel occlusion stroke. J Cardiovasc Dev Dis. 2024;11:107. doi: 10.3390/jcdd11040107</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11050543</ArticleId><ArticleId IdType="pubmed">38667725</ArticleId></ArticleIdList></Reference><Reference><Citation>Romoli M, Paciaroni M, Tsivgoulis G, Agostoni EC, Vidale S. Mothership versus drip-and-ship model for mechanical thrombectomy in acute stroke: a systematic review and meta-analysis for clinical and radiological outcomes. J Stroke. 2020;22:317&#x2013;323. doi: 10.5853/jos.2020.01767</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7568974</ArticleId><ArticleId IdType="pubmed">33053947</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghozy S, Hasanzadeh A, Kobeissi H, Abdelghaffar M, Shafie M, Beizavi Z, Hassankhani A, Azzam AY, Dmytriw AA, Kadirvel R, et al. The impact of off-hour mechanical thrombectomy therapy on outcomes for acute ischemic stroke: a systematic review and meta-analysis. J Neurol Sci. 2023;453:120802. doi: 10.1016/j.jns.2023.120802</Citation><ArticleIdList><ArticleId IdType="pubmed">37741122</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu Z, Li F, Sang H, Yuan G, Xie D, Zhou K, Li M, Meng Z, Kong Z, Ruan Z, et al. Intravenous tenecteplase before thrombectomy in stroke. N Engl J Med. 2025;393:139&#x2013;150. doi: 10.1056/nejmoa2503867</Citation><ArticleIdList><ArticleId IdType="pubmed">40396577</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Wijdeven RM, Duvekot MH, van der Geest PJ, Moudrous W, Dorresteijn KR, Wijnhoud AD, Mulder LJ, Alblas KC, Asahaad N, Kerkhoff H, et al. Determinants of door-in-door-out time in patients with ischaemic stroke transferred for endovascular thrombectomy. Eur Stroke J. 2023;8:667&#x2013;674. doi: 10.1177/23969873231177768</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10472962</ArticleId><ArticleId IdType="pubmed">37248995</ArticleId></ArticleIdList></Reference><Reference><Citation>Saver JL, Goyal M, Van der Lugt A, Menon BK, Majoie CB, Dippel DW, Campbell BC, Nogueira RG, Demchuk AM, Tomasello A, et al. ; HERMES Collaborators. Time to treatment with endovascular thrombectomy and outcomes from ischemic stroke: a meta-analysis. JAMA. 2016;316:1279&#x2013;1289. doi: 10.1001/jama.2016.13647</Citation><ArticleIdList><ArticleId IdType="pubmed">27673305</ArticleId></ArticleIdList></Reference><Reference><Citation>Saver JL, Chapot R, Agid R, Hassan AE, Jadhav AP, Liebeskind DS, Lobotesis K, Meila D, Meyer L, Raphaeli G, et al. Thrombectomy for distal, medium vessel occlusions: a consensus statement on present knowledge and promising directions. Stroke. 2020;51:2872&#x2013;2884. doi: 10.1161/strokeaha.120.028956</Citation><ArticleIdList><ArticleId IdType="pubmed">32757757</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernsen MLE, Goldhoorn RJB, Lingsma HF, Van Oostenbrugge RJ, Van Zwam WH, Uyttenboogaart M, Roos YB, Martens JM, Hofmeijer J, et al. ; MR CLEAN Registry investigators. Importance of occlusion site for thrombectomy technique in stroke: comparison between aspiration and stent retriever. Stroke. 2021;52:80&#x2013;90. doi: 10.1161/STROKEAHA.120.030031</Citation><ArticleIdList><ArticleId IdType="pubmed">33349023</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>